We are delighted to speak with Prof. Mariana Castells (Brigham and Women’s Hospital, Boston, MA) about Indolent Systemic Mastocytosis and Monoclonal Mast Cell Activation Syndrome.
The abstract entitled ‘A Phase 2/3 Study of BLU-263 in Patients with Indolent Systemic Mastocytosis or Monoclonal Mast Cell Activation Syndrome’ (Abstract #665) was presented at The American Academy of Allergy, Asthma & Immunology (AAAAI), February 25-28, 2022
- Could you tell us a little about indolent systemic mastocytosis and monoclonal mast cell activation syndrome, and the unmet needs in their management? (00:25)
Disclosures: Mariana Castells has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.
Filmed in coverage of the virtual AAAAI 2022.
Share this Video
Related Videos In Dermatological Diseases
Victoria P. Werth, ACR 2022: The phase 3 DeterMine trial of lenabasum in dermatomyositis
DeterMine (NCT03813160) was a phase 3 randomized, double-blind, placebo-controlled study investigating the efficacy and safety of lenabasum for the treatment of dermatomyositis. It was a pleasure to talk with Prof. Victoria P. Werth (University of Pennsylvania, Philadelphia, PA, USA) to discuss the aims, design, eligibility criteria and findings of the phase 3 study. This information […]
Loretta Fiorillo, EADV 2022: Findings from the Phase 3 Study of Apremilast in Paediatric Plaque Psoriasis
Apremilast is an oral small-molecule inhibitor of PDE4 currently approved in adult patients with plaque psoriasis. touchIMMUNOLOGY were delighted to talk with Dr. Loretta Fiorillo (University of Alberta, Edmonton, Canada) to discuss the the aims, design and eligibility criteria of the study investigating apremilast in paediatric patients with moderate to severe plaque psoriasis and how […]
Loretta Fiorillo, EADV 2022: Apremilast Treatment for Plaque Psoriasis in Paediatric Patients
Apremilast is an oral small-molecule inhibitor of PDE4 currently approved in adult patients with plaque psoriasis. It was a pleasure to talk with Dr. Loretta Fiorillo (University of Alberta, Edmonton, Canada) around the unmet needs in the treatment of plaque psoriasis in paediatric patients and the clinical evidence supporting apremilast in this indication. The abstract […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!